SEVERITY ASSESSMENT OF COMMUNITY9ACQUIRED PNEUMONIA IN REAL CLINICAL PRACTICE IN A MULTI9PROFILE HOSPITAL IN RUSSIA

We aimed to assess the criteria used by physicians in routine clinical practice to assess severity of communityacquired pneumonia (CAP) in adults. Methods. A survey of 165 physicians from multiprofile hospitals was performed at six Russian cities. Results. Chest Xray data were considered by 80% of respondents as an important marker to identify severe / non-severe CAP. Clinical features, comorbidity, laboratory abnormalities, and history data were noted by 78.8%; 66.1%; 55.8% and 23.6% of physicians, respectively. Severe dyspnea or tachypnea and confusion were the most often mentioned clinical criteria of severe CAP (78.8% of respondents for each, respectively). Lung tissue destruction was chosen as radiologic criterion of severe CAP in 80.6% of cases. Hyperleukocytosis and leukopenia were pointed as the most frequent laboratory abnormality related to severe CAP(89.7%). Only 10.3% of respondents used CAP prognostic scales. CAP prognostic scales recommended by national guidelines for adult patients (e.g. PORT и CURB/CRB65) were not usually used. Conclusion. Generally, physicians are aware of CAP prognostic criteria and key risk factors of poor prognosis. Additional efforts are needed for more efficient implementation of CAP prognostic scales recommended by national guidelines.

1. Morbidity of infectious diseases in Russian Federation. Available at: http://www.rospotrebnadzor.ru (in Russian).

2. Morbidity in population of Russian Federation. Federal Research Institute of Organization and Information in Healthcare, Healthcare Ministry of Russian Federation. Available at: http://www.mednet.ru (in Russian).

3. The global burden of disease: 2014 update. World Health Organization. Available from http://www.who.int

4. Gel'fand B.R., Saltanov A.I., eds. Intensive Therapy. National Handbook. Moscow: GEOTAR Media; 2011. V. 2 (in Russian).

5. Menéndez R., Reyes S., Martínez R. et al. Economic eval uation of adherence to treatment guidelines in nonintensive care pneumonia. Eur. Respir. J. 2007; 29 (4): 751–756.

6. Meehan T., Weingarten S., Holmboe E. et al. A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. Am. J. Med. 2001; 111: 203–210.

7. Benenson R., Magalski A., Cavanaugh S., Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad. Emerg. Med. 1999; 6: 1243–1248.

8. Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low risk patients with community acquired pneumonia. N. Engl. J. Med. 1997; 336: 243–250.

9. Lim W.S., van der Eerden M.M., Laing R. et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58: 377–382.

10. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S. et al. Clinical Guidelines on Diagnosis, Treatment and Prevention of Severe Community Acquired Pneumonia. Consilium Medicum. 2015; 17 (3): 8–37 (in Russian).

11. Macfarlane J., Rose D. Radiographic features of staphylococcal pneumonia in adults and children. Thorax. 1996; 51: 539–540.

12. Charles P.G.P., Wolfe R., Whitby M. et al. SMARTCOP: a tool for predicting the need for intensive respiratory or vasopressor support in community acquired pneumonia. Clin. Infect. Dis. 2008; 47: 375–384.

13. Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 2013; 41 (2): 580–637.

14. Chalmers J.D., Singanayagam A., Hill A.T. C reactive protein is an independent predictor of severity in community acquired pneumonia. Am. J. Med. 2008; 121: 219–225.

15. Nseir W., Farah R., Mograbi J. et al. Impact of serum C reactive protein measurements in the first 2 days on the 30 day mortality in hospitalized patients with severe community acquired pneumonia: A cohort study. J. Crit. Care. 2013; 28 (3): 291–295.

16. Zhydkov A., Christ Crain M., Thomann R. et al. Utility of procalcitonin, C reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community acquired pneumonia. Clin. Chem. Lab. Med. 2015; 53 (4): 559–566.